JP2018518151A5 - - Google Patents

Download PDF

Info

Publication number
JP2018518151A5
JP2018518151A5 JP2017550485A JP2017550485A JP2018518151A5 JP 2018518151 A5 JP2018518151 A5 JP 2018518151A5 JP 2017550485 A JP2017550485 A JP 2017550485A JP 2017550485 A JP2017550485 A JP 2017550485A JP 2018518151 A5 JP2018518151 A5 JP 2018518151A5
Authority
JP
Japan
Prior art keywords
seq
antibody
acid sequence
isolated
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2017550485A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018518151A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/024357 external-priority patent/WO2016160620A2/en
Publication of JP2018518151A publication Critical patent/JP2018518151A/ja
Publication of JP2018518151A5 publication Critical patent/JP2018518151A5/ja
Withdrawn legal-status Critical Current

Links

JP2017550485A 2015-03-27 2016-03-25 B7−h4発現充実性腫瘍を処置するためのcar t細胞 Withdrawn JP2018518151A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562139592P 2015-03-27 2015-03-27
US62/139,592 2015-03-27
PCT/US2016/024357 WO2016160620A2 (en) 2015-03-27 2016-03-25 Car t-cells for the treatment of b7-h4 expressing solid tumors

Publications (2)

Publication Number Publication Date
JP2018518151A JP2018518151A (ja) 2018-07-12
JP2018518151A5 true JP2018518151A5 (enExample) 2019-05-09

Family

ID=57007182

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017550485A Withdrawn JP2018518151A (ja) 2015-03-27 2016-03-25 B7−h4発現充実性腫瘍を処置するためのcar t細胞

Country Status (8)

Country Link
US (1) US20180118831A1 (enExample)
EP (1) EP3274369A4 (enExample)
JP (1) JP2018518151A (enExample)
CN (1) CN107531782A (enExample)
AU (1) AU2016243126A1 (enExample)
CA (1) CA2981143A1 (enExample)
IL (1) IL254700A0 (enExample)
WO (1) WO2016160620A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10814011B1 (en) 2017-06-16 2020-10-27 Nantbio, Inc. Anti-B7-H4 antibodies and methods
CA3067914A1 (en) 2017-06-30 2019-01-03 Cellectis Cellular immunotherapy for repetitive administration
BR112020003533A2 (pt) 2017-08-25 2020-11-17 Five Prime Therapeutics, Inc. anticorpos b7-h4 e métodos de uso dos mesmos
CN107903326B (zh) * 2018-01-02 2020-06-30 广东省人民医院(广东省医学科学院) 包含C3aR胞内结构域的嵌合抗原受体、慢病毒载体、表达细胞及药物
EP3753951A4 (en) * 2018-02-11 2022-03-16 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. ANTI-B7-H4 ANTIBODIES, ANTIGEN-BINDING FRAGMENT THEREOF AND PHARMACEUTICAL USE THEREOF
CN111741978A (zh) 2018-02-21 2020-10-02 戊瑞治疗有限公司 B7-h4抗体制剂
EP3759142A1 (en) 2018-03-02 2021-01-06 Five Prime Therapeutics, Inc. B7-h4 antibodies and methods of use thereof
KR102716165B1 (ko) * 2019-03-21 2024-10-15 쑤저우 카노바 바이오파마슈티컬 컴퍼니 리미티드 항-b7s1 폴리펩티드 및 이의 용도
US12180283B2 (en) 2019-08-01 2024-12-31 Immunitybio, Inc. Anti-B7-H4 chimeric antigen receptor-modified NK-92 cells
WO2021231959A1 (en) * 2020-05-15 2021-11-18 Precision Biosciences, Inc. Methods for immunotherapy
CN116635064A (zh) 2020-12-18 2023-08-22 世纪治疗股份有限公司 具有适应性受体特异性的嵌合抗原受体系统
CN113156120B (zh) * 2021-03-26 2022-03-25 中国医学科学院北京协和医院 B7h4在制备子宫内膜癌分子分型试剂及系统中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6468546B1 (en) * 1998-12-17 2002-10-22 Corixa Corporation Compositions and methods for therapy and diagnosis of ovarian cancer
NZ554725A (en) * 2004-10-25 2009-10-30 Merck & Co Inc Anti-ADDL antibodies and uses thereof
US7858752B2 (en) * 2006-12-05 2010-12-28 Abbott Laboratories Recombinant antibodies against hepatitis C virus and methods of obtaining and using same
AU2010254136B2 (en) * 2009-05-26 2016-09-29 Mount Sinai School Of Medicine Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof
EP2773651B1 (en) * 2011-11-03 2020-12-23 The Trustees of the University of Pennsylvania Isolated b7-h4 specific compositions and methods of use thereof
US9376485B2 (en) * 2012-02-29 2016-06-28 The Brigham And Women's Hospital, Inc. Neutralizing antibody for epstein barr virus-associated disease
CA2887129A1 (en) * 2012-10-09 2014-04-17 Igenica, Inc. Anti-c16orf54 antibodies and methods of use thereof
WO2014100439A2 (en) * 2012-12-19 2014-06-26 Amplimmune, Inc. B7-h4 specific antibodies, and compositions and methods of use thereof
EA201591750A1 (ru) * 2013-03-14 2016-05-31 Дженентек, Инк. Антитела против b7-h4 и иммуноконъюгаты
EP3037819A4 (en) * 2013-08-23 2017-03-29 Fujita Health University Method of determining resistance to influenza virus

Similar Documents

Publication Publication Date Title
JP2018511319A5 (enExample)
JP2018518151A5 (enExample)
KR102924006B1 (ko) 항-pd-l1/항-4-1bb 이중특이적 항체 및 이의 용도
KR102346988B1 (ko) 항 b7-h4 항체
Fisher et al. Generation and preclinical characterization of an antibody specific for SEMA4D
TWI878541B (zh) 抗cldn18.2抗體及其診斷用途
JP2018524973A5 (enExample)
JP2012012402A5 (enExample)
CN118459593A (zh) 抗b7-h3抗体及其用途
JP2018518152A5 (enExample)
CN111995682B (zh) 抗人SIRPα单克隆抗体及其用途
JP2013506428A5 (enExample)
JP2014527398A5 (enExample)
TW201829467A (zh) 抗cd3抗體及含有該抗體的分子
JP2018505681A5 (enExample)
CN113683697B (zh) 抗b7-h3抗体、其制备方法及用途
JP2020513769A (ja) 抗lair1抗体およびその使用
WO2021097800A1 (en) Anti-pd-l1/anti-b7-h3 multispecific antibodies and uses thereof
CN111620949A (zh) 结合人lag-3的抗体、其制备方法和用途
JP2021505663A5 (enExample)
WO2018162944A1 (en) Recombinant antibodies to programmed death 1 (pd-1) and uses therefor
WO2014192974A1 (ja) 抗lgr6抗体を含む癌の検出用又は診断用試薬
JP7082112B2 (ja) 抗gpr20抗体
CN113527484A (zh) 抗cd47单克隆抗体
CN109593135B (zh) 抗人pd-l1单克隆抗体及其应用